Viridian Therapeutics Inc (VRDN NASDAQ) stock market data APIs
$16.4708
0.61(3.8%)
as of March 13, 2025
Viridian Therapeutics Inc Financial Data Overview
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Prev. Close
15.865
Open
16.4708
High
16.6299
Low
15.6618
52 wk Range
11.4-27.2
Market Cap
1 288 M
Shares Outstanding
81 485 K
Revenue
302 K
EPS
-0.81
Beta
1.088
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viridian Therapeutics Inc data using free add-ons & libraries
Get Viridian Therapeutics Inc Fundamental Data
Viridian Therapeutics Inc Fundamental data includes:
- Net Revenue: 302 K
- EBITDA: -298 495 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-25
- EPS/Forecast: -1.0442
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viridian Therapeutics Inc News
New
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc
Overview of the Recent Trade On September 30, 2024, State Street Corp executed a significant transaction involving Viridian Therapeutics Inc (NASDAQ:VRDN), a key player in the biopharmaceutical indus...
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 B...
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
- Supply agreement supports Viridian’s development of potential first- and best-in-class subcutaneous therapies for treatment of thyroid eye disease (TED) - - Ypsomed brings strong track record of ...
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
The Nasdaq Composite (NASDAQINDEX: ^IXIC) has performed extraordinarily well in 2023, getting off to its best first half of a year since the 1980s. Stock index futures suggested the Nasdaq would post ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
